Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGN-259 for Neurotrophic Keratopathy (SEER-1)
NCT02600429Phase 3Terminated
- Sponsor
- ReGenTree
- Start
- Sep 2015
- Primary completion
- Nov 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of timbetasin in neurotrophic keratopathy (NK), sponsored by ReGenTree. Started Sep 2015; status: terminated.
02
Drugs
timbetasin
03
Conditions
neurotrophic keratopathy (NK)
Beyond the preview
Go deeper on NCT02600429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02600429.